Kaposi's sarcoma primary prevention: Difference between revisions
Jump to navigation
Jump to search
Farima Kahe (talk | contribs) No edit summary |
Farima Kahe (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
There are no established measures for the primary prevention of kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease such as avoiding high risk behavior and using antiviral | There are no established measures for the primary prevention of kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease such as avoiding high risk behavior and using [[antiviral drugs]]. | ||
==Primary Prevention== | ==Primary Prevention== | ||
There are no established measures for the primary prevention of kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease as followings:<ref name="pmid17089802">{{cite journal |vauthors=Casper C, Wald A |title=The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma |journal=Curr. Top. Microbiol. Immunol. |volume=312 |issue= |pages=289–307 |date=2007 |pmid=17089802 |doi= |url=}}</ref><ref name="Goedert2002">{{cite journal|last1=Goedert|first1=J. J.|title=Risk Factors for Classical Kaposi's Sarcoma|journal=CancerSpectrum Knowledge Environment|volume=94|issue=22|year=2002|pages=1712–1718|issn=14602105|doi=10.1093/jnci/94.22.1712}}</ref> | There are no established measures for the primary prevention of kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease as followings:<ref name="pmid17089802">{{cite journal |vauthors=Casper C, Wald A |title=The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma |journal=Curr. Top. Microbiol. Immunol. |volume=312 |issue= |pages=289–307 |date=2007 |pmid=17089802 |doi= |url=}}</ref><ref name="Goedert2002">{{cite journal|last1=Goedert|first1=J. J.|title=Risk Factors for Classical Kaposi's Sarcoma|journal=CancerSpectrum Knowledge Environment|volume=94|issue=22|year=2002|pages=1712–1718|issn=14602105|doi=10.1093/jnci/94.22.1712}}</ref> | ||
*Avoiding risky sexual practices, such as having unprotected sex | *Avoiding risky sexual practices, such as having [[unprotected sex]] | ||
*Avoiding using intravenous (IV) needles that have been used by someone else | *Avoiding using intravenous (IV) needles that have been used by someone else | ||
*Use antiviral drugs | *Use [[antiviral drugs]] | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 14:40, 19 September 2018
|
Kaposi's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Kaposi's sarcoma primary prevention On the Web |
|
American Roentgen Ray Society Images of Kaposi's sarcoma primary prevention |
|
Risk calculators and risk factors for Kaposi's sarcoma primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Farima Kahe M.D. [2]
Overview
There are no established measures for the primary prevention of kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease such as avoiding high risk behavior and using antiviral drugs.
Primary Prevention
There are no established measures for the primary prevention of kaposi's sarcoma. However, there are some measures to significantly lower the risk of disease as followings:[1][2]
- Avoiding risky sexual practices, such as having unprotected sex
- Avoiding using intravenous (IV) needles that have been used by someone else
- Use antiviral drugs
References
- ↑ Casper C, Wald A (2007). "The use of antiviral drugs in the prevention and treatment of Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma". Curr. Top. Microbiol. Immunol. 312: 289–307. PMID 17089802.
- ↑ Goedert, J. J. (2002). "Risk Factors for Classical Kaposi's Sarcoma". CancerSpectrum Knowledge Environment. 94 (22): 1712–1718. doi:10.1093/jnci/94.22.1712. ISSN 1460-2105.